Published on 04 April 2022
Sourcing innovator products in the age of biosimilar research
Author(s): Michael Cohan
Innovator drug sourcing challenges
1.244 views
Articles
Published on 10 January 2024
Latest features in GaBI Journal, 2023, Issue 3
The articles in this issue of the GaBI Journal highlight two important issues that must be considered when reading scientific publications. The first two articles illustrate the rapidly expanding influence...
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2023.1203.012
1.179 views
Published on 03 January 2023
2022/3 GaBI Journal Table of Contents
Contents Editor’s Letter The importance of trust Original Research Social trust and regional variation in the adoption of biosimilars in Italy and Germany US prescribers’ attitudes and perceptions about biosimilars Review...
1.120 views
Published on 25 January 2024
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Submitted: 4 November 2023; Revised: 24 November 2023; Accepted: 27 November 2023; Published online first: 28 November 2023 A study by Meijboom et al. aimed to compare the risk of and...
DOI: 10.5639/gabij.2023.1203.017
1.102 views
Published on 11 July 2024
First 2024 GaBI Journal issue highlights
It was with great pleasure that I assumed the role of Editor-in-Chief (EiC) of GaBI Journal in January of this year. Taking over the helm from Professor Philip D Walson...
Author(s): Robin Thorpe, PhD, FRCPath
DOI: 10.5639/gabij.2024.1301.001
1.031 views
Published on 29 November 2022
2022/2 GaBI Journal Table of Contents
Contents Editor’s Letter What to look forward to in GaBI Journal, 2022, Issue 2 Commentary Substitution and interchangeability: time for a conversation? Original Research On statistical evaluation for interchangeability of...
1.018 views
Published on 06 May 2024
Physicochemical stability of Azacitidine Accord 25 mg/mL suspension for injection in original vials and polypropylene syringes after reconstitution with refrigerated water for injection
Abstract: The physicochemical stability of Azacitidine Accord, a pyrimidine analogue antineoplastic agent, was assessed after reconstitution with cold water for injection (WFI) and storage in original glass vials and polypropylene...
Author(s): Irene Krämer, PhD, Frank Erdnuess, PhD, Judith Thiesen, PhD
azacitidine, physicochemical stability, suspension for injection
DOI: 10.5639/gabij.2024.1302.023
991 views
Published on 11 September 2024
Physicochemical stability of Fluorouracil Accord in three different concentrations in portable elastomeric infusion pumps
Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of Fluorouracil Accord 50 mg/mL solution for injection...
concentrated solution, diluted infusion solution, elastomeric infusion pump, fluorouracil, physicochemical stability
DOI: 10.5639/gabij.2024.1302.025
934 views
Published on 11 September 2024
Physicochemical stability of Cisplatin Accord in punctured original vials, syringes and after dilution with 0.9% sodium chloride solution
Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of undiluted Cisplatin Accord 1 mg/mL in punctured...
cisplatin, concentrated solution, diluted infusion solution, HPLC, physicochemical stability
DOI: 10.5639/gabij.2024.1302.021
855 views
Published on 11 September 2024
Physicochemical stability of Carboplatin Accord in punctured original vials, syringes and after dilution with 0.9% sodium chloride or 5% glucose solution
Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of undiluted Carboplatin Accord 10 mg/mL in punctured...
carboplatin, concentrated solution, diluted infusion solution, HPLC, physicochemical stability
DOI: 10.5639/gabij.2024.1302.020
841 views
Published on 07 November 2024
Transforming health care: CinnaGen’s leadership in follow-on biologicals/biosimilars development and market expansion
Abstract: CinnaGen, the largest biopharmaceutical company in the MENA region, is a leader in developing follow-on biologicals/biosimilars. Dr Haleh Hamedifar, Chairperson of CinnaGen, spoke to GaBI (Generics and Biosimilars Initiative)...
Author(s): GaBI Journal Editor
biosimilars, clinical development, commercialization, MENA (Middle East and North Africa)
DOI: 10.5639/gabij.2024.1303.037
809 views
Published on 11 September 2024
Physicochemical stability of Oxaliplatin Accord 5 mg/mL in punctured original vials and after dilution with 5% glucose solution in polyethylene bottles and polyolefine bags
Author byline as per print journal: Irene Krämer, PhD; Frank Erdnuess, PhD; Judith Thiesen, PhD Study objectives: To determine the physicochemical stability of Oxaliplatin Accord 5 mg/mL in punctured original...
concentrated solution, diluted infusion solution, oxaliplatin, physicochemical stability
DOI: 10.5639/gabij.2024.1302.022
805 views
Advertisement
